Charles Lu

Charles Lu

Auto-generated profile, based on publicly available information

Charles Lu

Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2025 in Cancer and Metastasis Reviews
Verified
Journal Article
Closed access
PDF file
XZXin Ming M. Zhou
Xin Ming M. Zhou
ADAnjali J. D’aMiano
Anjali J. D’aMiano
CLCharles Lu
Charles Lu
VMVrinda Madan
Vrinda Madan
SKSara Khoshniyati
Sara Khoshniyati
JSJoel C Sunshine
Joel C Sunshine

14 October 2023 in SLAS Discovery
Verified
Journal Article
Open access
KBKari Barlan
Kari Barlan
GBGaurang P Bhide
Gaurang P Bhide
DWDerek R White
Derek R White
MLMarc R Lake
Marc R Lake
CLCharles Lu
Charles Lu
CHChen-Lin Hsieh
Chen-Lin Hsieh
N-linked glycosylation is a common post-translational modification that has various effects on multiple types of proteins. The extent to which an N-linked glycoprotein is modified and the identity of glycans species involved is of great interest to the biopharmaceutical industry, since glycosylation can impact the efficacy and safety of therapeutic monoclonal antibodies (mAbs). mAbs lacking core fucose, for example, display enhanced clinical efficacy through increased antibody-dependent cellular cytotoxicity. We performed a genome-wide CRISPR knockout screen in Chinese hamster ovary (CHO) cells, the workhorse cell culture system for industrial production of mAbs, aimed at identifying novel regulators of protein fucosylation. Using a lectin binding assay, we identified 224 gene perturbations that significantly alter protein fucosylation, including well-known glycosylation genes. This functional genomics framework could readily be extended and applied to study the genetic pathways involved in regulation of other glycoforms. We hope this resource will provide useful guidance toward the development of next generation CHO cell lines and mAb therapeutics.

12 November 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
PMPaul Morrison
Paul Morrison
TTTina Tang
Tina Tang
CLCharles Lu
Charles Lu
SMShamim Mollah
Shamim Mollah
Motivation: Networks are ubiquitous to organize and represent data in the real world such as the biomedical networks, social networks, etc. Due to the attractive property of networks which can explicitly capture the rich relationships among data samples, there is an increasing demand to transform linkage-free data to graph-structure data for efficient downstream analyses. Existing works typically focus on representing a single data object like gene expression profile in a homogeneous 2D network, which fail to deal with situations where two different data objects are involved to create a 3D heterogeneous network. Results: In this paper, we introduce an R package, gen3DNet (a generic version of the iPhDNet), for generating 3D network models from two correlated objects with shared common factors. Specifically, gen3DNet builds the relationships between samples and shared factors using the non-negative matrix factorization, where three clustering techniques are evaluated to determine the number of functional modules. In addition, it builds the relationships between samples from the two distinct data objects based on a partial least squares regression model. Usage of the package is illustrated through a real-world application. GitHub URL Source code is available at https://github.com/mollahlab/gen3DNet

23 June 2025 in medRxiv
Verified
Preprint
Open access
PDF file
GWGuihong Wan
Guihong Wan
NNNga Thi Nguyen
Nga Thi Nguyen
CLCharles Lu
Charles Lu
SKSara Khattab
Sara Khattab
BYBoshen Yan
Boshen Yan
YSYevgeniy Semenov
Yevgeniy Semenov
Background Systemic immunosuppression (sISP), particularly with glucocorticoids, is commonly used among patients receiving immune checkpoint inhibitor (ICI) therapy. Although recent studies have demonstrated that sISP is associated with poor outcomes in ICI recipients, there is limited information on how the timing, dose, and duration of sISP affect overall survival (OS). This multi-cohort retrospective study aims to address these gaps. Methods This study included 13,086 ICI recipients from Massachusetts General Hospital, Brigham and Women’s Hospital, and Dana-Farber Cancer Institute (MGBD) between May 31, 2015, and October 11, 2021. For independent validation, 26,172 ICI recipients were identified from the TriNetX database between April 30, 2010, and October 11, 2021, using 2:1 propensity score matching. Multivariable survival analyses were conducted with Accelerated Failure Time (AFT) models, reporting Time Ratios (TRs) and 95% Confidence Intervals (CIs), where TR<1 indicates shorter OS. Findings In the MGBD cohort, sISP within one year of ICI initiation was associated with worse OS compared to patients without sISP via landmark analysis. This association was accentuated among patients receiving sISP closer to ICI initiation, with those receiving sISP within one month of ICI initiation having the worst outcomes (TR: 0.49; 95% CI: 0.44-0.54; p<0.0001). Increased dose and duration of sISP were associated with a greater survival time loss, such that doses beyond 60 mg/day had a 40% survival time loss and durations longer than 7 days were associated with a 35% survival time loss. These findings were independently validated in the TriNetX cohort. Interpretation Three key factors are associated with significantly worse OS: sISP near ICI initiation, higher sISP dose, and longer sISP duration, regardless of indication. These findings provide clinicians with valuable information to guide sISP management among ICI recipients. Funding NIH, USA Evidence before this study We reviewed PubMed and existing literature for studies on systemic immunosuppression (sISP), particularly glucocorticoids, and outcomes among immune checkpoint inhibitor (ICI) recipients. Previous research, including clinical trial studies, indicated that sISP, especially at higher doses or for managing immune-related adverse events (irAEs), was associated with poorer survival. However, studies were limited by small sample sizes, focused on single cancer types, or did not comprehensively assess the nuanced impacts of sISP timing relative to ICI initiation, dose, and duration across diverse cancer types and ICI indications. Thus, a clear understanding of these specific parameters in large, real-world cohorts was lacking. Added value of this study This multi-cohort study analyzed approximately 40,000 ICI recipients, leveraging data from a large academic medical center system (MGBD) and validating findings in a national, population-level database (TriNetX) with access to granular patient-level data. We comprehensively investigated how the timing, dose, and duration of systemic glucocorticoid immunosuppression influence overall survival across a pan-cancer population. Our large scale and detailed approach provide robust, generalizable insights into these critical factors, addressing limitations of prior, smaller, or more narrowly focused investigations. Implications of all the available evidence Our findings offer clinicians critical, actionable insights for managing systemic glucocorticoid immunosuppression in patients receiving ICI therapy. Knowing that sISP administered near ICI initiation, at higher doses, or for longer durations is associated with significantly worse overall survival can guide clinical decision-making. This allows for more informed risk-benefit discussions, strategies to minimize steroid exposure when feasible (e.g., lowest effective dose, shortest duration), and consideration of steroid-sparing alternatives, ultimately aiming to optimize survival outcomes for cancer patients on ICI therapy.

2 December 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
CLCharles Lu
Charles Lu
RSRintsen Sherpa
Rintsen Sherpa
LKLiubou Klindziuk
Liubou Klindziuk
SKStefanie Kriel
Stefanie Kriel
SMShamim Mollah
Shamim Mollah
MSMin Shi
Min Shi
Motivation An in-depth understanding of epithelial breast cell responses to the growth-promoting ligands is required to elucidate how the microenvironment (ME) signals affect cell-intrinsic regulatory networks and the cellular phenotypes they control, such as cell growth, progression, and differentiation. This is particularly important in understanding the mechanisms of breast cancer initiation and progression. However, the current mechanisms by which the ME signals influence these cellular phenotypes are not well established. Results We developed a high-order correlation method using proteomics data to reveal the regulatory dynamics among proteins, histones, and six growth-promoting ligands in the MCF10 cell line. In the proposed method, the protein-ligand and histone-ligand correlations at multiple time points are first encoded in two three-way tensors. Then, a non-negative tensor factorization model is used to capture and quantify the protein-ligand and histone-ligand correlations spanning all time points, followed by a partial least squares regression process to model the correlations between histones and proteins. Our method revealed the onset of specific protein-histone signatures in response to growth ligands contributing to distinct cellular phenotypes that are indicative of breast cancer initiation and progression. Contact smollah{at}wustl.edu